TTrialPathMatch Me to Trials
← Back to trials
RecruitingMajor Depressive Disorder

Optimizing Brain Excitability in Depression

Eligible age

18–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).

Sponsor: Stanford University

You may qualify if…

  • Men and women, ages 18 to 65
  • Diagnosis of major depressive disorder, assessed through a Structured Clinical Interview for DSM-5 (SCID-5)
  • In a current depressive episode, assessed through a Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (SCID-5)
  • Moderate-to-severe depression as indicated by a score between 11-20 on the Quick Inventory of Depressive Symptoms (QIDS)
  • Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales
  • No current or history of neurological disorders
  • No seizure disorder or risk of seizures
  • Neurosurgical patients: Men and women ages 18-65 with medication-refractory epilepsy who are admitted for phase II intracranial monitoring to detect a seizure focus will be considered appropriate for this study. Participants must have the intellectual capacity to understand the consent process and agree to the study.

You may not qualify if…

  • Those with a contraindication for MRIs (e.g. implanted metal)
  • History of head trauma with loss of consciousness
  • History of seizures or on medications that reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium)
  • Neurological or uncontrolled medical disease
  • Any unstable medical condition
  • Active substance abuse
  • Diagnosis of psychotic or bipolar disorder
  • A prior history of Electroconvulsive Therapy (ECT) failure

Where it's recruiting

California

Iowa City · Stanford

Source: ClinicalTrials.gov · NCT07242105 · last updated 2026-02-10